Piper Sandler Maintains Masimo(MASI.US) With Buy Rating, Raises Target Price to $180

派杰投资维持麦斯莫医疗(MASI.US)买入评级，上调目标价至180美元

moomoo资讯 · 11/06 08:37 · 评级/大行评级

Piper Sandler analyst Jason Bednar maintains $Masimo (MASI.US)$ with a buy rating, and adjusts the target price from $165 to $180.

According to TipRanks data, the analyst has a success rate of 41.3% and a total average return of -5.7% over the past year.

AnalystRecentRatingAutoNews_205777_20241106_8eb4bee5197094bf6f8b8ee823e50c7a1beacb3e_1730899876987391_mm_en

Furthermore, according to the comprehensive report, the opinions of $Masimo (MASI.US)$'s main analysts recently are as follows:

The recent earnings outperformance and uplift in guidance by Masimo are seen positively, particularly in light of the swift actions by new management and the board to improve the company's profit and loss statement. Coupled with robust consumables revenue growth and effective hospital contracting, it is anticipated that Masimo will excel in the fourth quarter and continue this trajectory into 2025.
Following quarterly results, the emphasis has shifted towards the year 2025, with the expectation of at least a 26% operating margin for stand-alone healthcare, reflecting an increase of 200 basis points from earlier projections. A subsequent strategic update is anticipated in January.

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

派杰投资分析师Jason Bednar维持$麦斯莫医疗 (MASI.US)$买入评级，并将目标价从165美元上调至180美元。

根据TipRanks数据显示，该分析师近一年总胜率为41.3%，总平均回报率为-5.7%。

AnalystRecentRatingAutoNews_205777_20241106_8eb4bee5197094bf6f8b8ee823e50c7a1beacb3e_1730899876987391_mm_sc

此外，综合报道，$麦斯莫医疗 (MASI.US)$近期主要分析师观点如下：

麦斯莫医疗最近的收益超出表现和指引的提升被视为积极的，尤其是在新管理层和董事会迅速行动改善公司的损益表的背景下。伴随着强劲的耗材营收增长和有效的医院合同，预计麦斯莫将在第四季度表现出色，并延续这一轨迹进入2025年。
在季度业绩发布后，重点转向了2025年，预计独立医疗保健部门的营业利润率至少达到26％，这反映了比早期预测高出200个基点。预计将在一月进行后续的战略更新。

提示:

TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。

TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。

分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。

总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。更多信息

Piper Sandler Maintains Masimo(MASI.US) With Buy Rating, Raises Target Price to $180

Piper Sandler Maintains Masimo(MASI.US) With Buy Rating, Raises Target Price to $180

风险及免责提示

声明